Articles from Breyer Capital

Breyer Capital, a premier venture capital investor focused on backing high-impact entrepreneurs, today announced the appointment of Dr. Bret Bostwick as Venture Advisor. Dr. Bostwick will work closely with Dr. Morgan Cheatham, Partner and Head of Healthcare & Life Sciences at Breyer Capital, who leads the firm’s investment strategy in the sector, and with Founder and CEO Jim Breyer. Together, they will continue to build an integrated healthcare and life sciences investment platform spanning drug discovery through care delivery. In this role, Dr. Bostwick will strengthen investment, incubation, and portfolio efforts across therapeutics and life sciences, contributing translational and clinical judgment to Breyer Capital’s healthcare and life sciences practice.

Breyer Capital, a premier global venture capital and private equity investor focused on catalyzing high-impact entrepreneurs, today announced an investment in Sandbox AQ, an enterprise software company delivering SaaS solutions that leverage quantum tech and AI, which launched today. In addition, Breyer Capital Founder and CEO Jim Breyer has joined the company’s board of advisors.

Breyer Capital, a premier global investment firm focused on backing high-impact entrepreneurs, today announced that Morgan Cheatham has joined the firm as a Partner and Head of Healthcare and Life Sciences. In this new role, Cheatham will lead Breyer Capital’s efforts in early-stage healthcare and life sciences investing – spearheading the firm’s practice and focusing on breakthrough biomedical technologies and innovative models of care. He will partner closely with founder Jim Breyer and the firm’s healthcare and life sciences portfolio companies, including OpenEvidence, Artera, Arena Bioworks, Atropos Health, Cleerly, Iterative Health, Slope, and SandboxAQ.